Pazopanib: an antiangiogenic drug in perspective. (Q37630567)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19903063 AND SRC:MED&resulttype=core&format=json

12 February 2020

review article

1 reference

title

Pazopanib: an antiangiogenic drug in perspective (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19903063 AND SRC:MED&resulttype=core&format=json

12 February 2020

main subject

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

author

Carlos Arturo Castañeda

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19903063 AND SRC:MED&resulttype=core&format=json

12 February 2020

Henry Leonidas Gómez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19903063 AND SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Carlos A Castaneda

1

1 reference

21 August 2017

Henry L Gomez

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19903063 AND SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19903063 AND SRC:MED&resulttype=core&format=json

12 February 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19903063 AND SRC:MED&resulttype=core&format=json

12 February 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19903063 AND SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

1335-1348

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19903063 AND SRC:MED&resulttype=core&format=json

Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis

12 February 2020

cites work

1 reference

Tumoral angiogenesis: review of the literature

21 January 2018

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor

21 January 2018

1 reference

Pazopanib: a novel multitargeted tyrosine kinase inhibitor

21 January 2018

1 reference

Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies

21 January 2018

1 reference

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

21 January 2018

1 reference

Translocation t(12;21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

21 January 2018

1 reference

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

21 January 2018

1 reference

Vascular changes in hepatocellular carcinoma

21 January 2018

1 reference

21 January 2018

Angiogenesis in gliomas

1 reference

Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors

21 January 2018

1 reference

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

21 January 2018

1 reference

Angiogenesis in endocrine tumors.

21 January 2018

1 reference

Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.

21 January 2018

1 reference

Antiangiogenic therapy in nonsmall cell lung cancer.

21 January 2018

1 reference

Angiogenesis as a strategic target for ovarian cancer therapy

21 January 2018

1 reference

Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma

21 January 2018

1 reference

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).

21 January 2018

1 reference

Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas

21 January 2018

1 reference

Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma

21 January 2018

1 reference

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

21 January 2018

1 reference

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions

21 January 2018

1 reference

21 January 2018

1 reference

Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma

21 January 2018

1 reference

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.

21 January 2018

1 reference

HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors

21 January 2018

1 reference

Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor

21 January 2018

1 reference

Recurrent priapism related to oxaliplatin infusion

21 January 2018

1 reference

Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets

21 January 2018

1 reference

Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies

21 January 2018

1 reference

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

21 January 2018

1 reference

Adverse effects of anticancer agents that target the VEGF pathway

21 January 2018

1 reference

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

21 January 2018

1 reference

Survival after second primary neoplasms of the brain or spinal cord in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.09.112

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19903063 AND SRC:MED&resulttype=core&format=json

12 February 2020

1 reference